superior industrial supply co. blue logo
0

Blog Layout

Methamphetamine

Methamphetamine (also called meth, crystal, chalk, and ice, among other terms) is an extremely addictive stimulant drug that is chemically similar to amphetamine. It takes the form of a white, odorless, bitter-tasting crystalline powder.


Methamphetamine is taken orally, smoked, snorted, or dissolved in water or alcohol and injected. Smoking or injecting the drug delivers it very quickly to the brain, where it produces an immediate, intense euphoria. Because the pleasure also fades quickly, users often take repeated doses, in a “binge and crash” pattern.


Methamphetamine increases the amount of the neurotransmitter dopamine, leading to high levels of that chemical in the brain. Dopamine is involved in reward, motivation, the experience of pleasure, and motor function. Methamphetamine’s ability to release dopamine rapidly in reward regions of the brain produces the euphoric “rush” or “flash” that many users experience. Repeated methamphetamine use can easily lead to addiction—a chronic, relapsing disease characterized by compulsive drug seeking and use.

Methamphetamine can be prescribed by a doctor to treat attention deficit hyperactivity disorder and other conditions, although it is rarely used medically, and only at doses much lower than those typically abused. It is classified as a Schedule II drug, meaning it has a high potential for abuse and is available only through a prescription that cannot be refilled.


People who use methamphetamine long-term may experience anxiety, confusion, insomnia, and mood disturbances and display violent behavior. They may also show symptoms of psychosis, such as paranoia, visual and auditory hallucinations, and delusions (for example, the sensation of insects crawling under the skin).


Chronic methamphetamine use is accompanied by chemical and molecular changes in the brain. Imaging studies have shown changes in the activity of the dopamine system that are associated with reduced motor skills and impaired verbal learning. In studies of chronic methamphetamine users, severe structural and functional changes have been found in areas of the brain associated with emotion and memory, which may account for many of the emotional and cognitive problems observed in these individuals.

Some of these brain changes persist long after methamphetamine use is stopped, although some may reverse after being off the drug for a sustained period (e.g., more than 1 year).


Most of the methamphetamine abused in the United States is manufactured in “superlabs” here or, more often, in Mexico. But the drug is also easily made in small clandestine laboratories, with relatively inexpensive over-the-counter ingredients such as pseudoephedrine, a common ingredient in cold medicines. To curb production of methamphetamine, pharmacies and other retail stores are required by law to keep logs of purchases of products containing pseudoephedrine; individuals may only purchase a limited amount of those products on a single day.


Methamphetamine production also involves a number of other, very hazardous chemicals. Toxicity from these chemicals can remain in the environment around a methamphetamine production lab long after the lab has been shut down, causing a wide range of health problems for people living in the area. (See the Methamphetamine Labs link).


What Are the Other Health Effects of Methamphetamine?

Taking even small amounts of methamphetamine can result in many of the same physical effects as those of other stimulants, such as cocaine or amphetamines. These include increased wakefulness, increased physical activity, decreased appetite, increased respiration, rapid heart rate, irregular heartbeat, increased blood pressure, and increased body temperature.


Long-term methamphetamine use has many negative consequences for physical health, including extreme weight loss, severe dental problems (“meth mouth”), and skin sores caused by scratching.


Methamphetamine use also raises the risk of contracting infectious diseases like HIV and hepatitis B and C. These can be contracted both by sharing contaminated drug injection equipment and through unsafe sex. Regardless of how it is taken, methamphetamine alters judgment and inhibition and can lead people to engage in these and other types of risky behavior.


Methamphetamine use may also worsen the progression of HIV/AIDS and its consequences. Studies indicate that HIV causes more injury to neurons and greater cognitive impairment in individuals who are HIV-positive and use methamphetamine than it does in HIV-positive people who do not use the drug.


By Bob Hansen January 29, 2022
Zyprexa (Olanzapine) is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder. More information/images in the Prescription Drug Brochure. When you receive Zyprexa extended-release injection, the medication is usually released slowly into your blood over a period of time. However, when you receive olanzapine extended-release injection, there is a small chance that olanzapine may be released into your blood too quickly. If this happens, you may experience a serious problem called Post-injection Delirium Sedation Syndrome (PDSS). If you develop PDSS, you may experience dizziness, confusion, difficulty thinking clearly, anxiety, irritability, aggressive behavior, weakness, slurred speech, difficulty walking, muscle stiffness or shaking, seizures, drowsiness, and coma (loss of consciousness for a period of time). You are most likely to experience these symptoms during the first 3 hours after you receive the medication. You will receive Zyprexa extended-release injection in a hospital, clinic, or another medical facility where you can receive emergency medical treatment if it is needed. You will need to remain in the facility for at least 3 hours after you receive the medication. While you are in the clinic, the medical staff will watch you closely for signs of PDSS. When you are ready to leave the facility, you will need a responsible person to be with you, and you should not drive a car or operate machinery for the rest of the day. Get emergency medical help right away if you experience any symptoms of PDSS after you leave the facility. A program has been set up to help people receive Zyprexa extended-release injection safely. You will need to register and agree to the rules of this program before you receive olanzapine extended-release injection. Your doctor, the pharmacy that dispenses your medication, and the medical facility where you receive your medication will also need to register. Ask your doctor if you have any questions about this program. For people being treated with olanzapine extended-release injection or Zyprexa injection: Studies have shown that older adults with dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and that may cause changes in mood and personality) who take antipsychotics (medications for mental illness) such as olanzapine have an increased chance of death during treatment. Older adults with dementia may also have a greater chance of having a stroke or mini-stroke during treatment. Olanzapine injection and olanzapine extended-release injection are not approved by the Food and Drug Administration (FDA) for the treatment of behavior disorders in older adults with dementia. Talk to the doctor who prescribed this medication if you, a family member, or someone you care for has dementia and is being treated with olanzapine injection or olanzapine extended-release injection. For more information visit the FDA website: http://www.fda.gov/Drugs Your doctor or pharmacist will give you the manufacturer’s patient information sheet (Medication Guide) when you begin treatment with olanzapine extended-release injection and each time you receive an injection. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer’s website to obtain the Medication Guide. extended-release injection, the medication is usually released slowly into your blood over a period of time. However, when you receive olanzapine extended-release injection, there is a small chance that olanzapine may be released into your blood too quickly. If this happens, you may experience a serious problem called Post-injection Delirium Sedation Syndrome (PDSS). If you develop PDSS, you may experience dizziness, confusion, difficulty thinking clearly, anxiety, irritability, aggressive behavior, weakness, slurred speech, difficulty walking, muscle stiffness or shaking, seizures, drowsiness, and coma (loss of consciousness for a period of time). You are most likely to experience these symptoms during the first 3 hours after you receive the medication. You will receive olanzapine extended-release injection in a hospital, clinic, or another medical facility where you can receive emergency medical treatment if it is needed. You will need to remain in the facility for at least 3 hours after you receive the medication. While you are in the clinic, the medical staff will watch you closely for signs of PDSS. When you are ready to leave the facility, you will need a responsible person to be with you, and you should not drive a car or operate machinery for the rest of the day. Get emergency medical help right away if you experience any symptoms of PDSS after you leave the facility. A program has been set up to help people receive olanzapine extended-release injection safely. You will need to register and agree to the rules of this program before you receive olanzapine extended-release injection. Your doctor, the pharmacy that dispenses your medication, and the medical facility where you receive your medication will also need to register. Ask your doctor if you have any questions about this program. For people being treated with olanzapine extended-release injection or olanzapine injection: Studies have shown that older adults with dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and that may cause changes in mood and personality) who take antipsychotics (medications for mental illness) such as olanzapine have an increased chance of death during treatment. Older adults with dementia may also have a greater chance of having a stroke or mini-stroke during treatment. Olanzapine injection and olanzapine extended-release injection are not approved by the Food and Drug Administration (FDA) for the treatment of behavior disorders in older adults with dementia. Talk to the doctor who prescribed this medication if you, a family member, or someone you care for has dementia and is being treated with olanzapine injection or olanzapine extended-release injection. For more information visit the FDA website: http://www.fda.gov/Drugs  Your doctor or pharmacist will give you the manufacturer’s patient information sheet (Medication Guide) when you begin treatment with olanzapine extended-release injection and each time you receive an injection. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer’s website to obtain the Medication Guide.
By Bob Hansen January 29, 2022
Zoloft (Sertraline) is included in the class of drugs called selective serotonin reuptake inhibitors (SSRIs). This class of drugs is used to treat depression, anxiety, and other mood disorders.
By Bob Hansen January 29, 2022
Zanaflex (Tizanidine) is a short-acting muscle relaxer. Tizanidine is used to relieve the spasms and increased muscle tone caused by multiple sclerosis (MS, a disease in which the nerves do not function properly and patients may experience weakness, numbness, loss of muscle coordination and problems with vision, speech, and bladder control), stroke, or brain or spinal injury. Tizanidine is in a class of medications called skeletal muscle relaxants. It works by slowing action in the brain and nervous system to allow the muscles to relax. Tizanidine comes as a tablet and a capsule to take by mouth. It is usually taken consistently either always with or always without food two or three times a day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take tizanidine exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Tizanidine capsules may be opened and sprinkled on soft foods such as applesauce. Talk to your doctor before opening the capsules because the effects of the medication, when used in this manner, may be different than when swallowing the capsule whole. The medication in the capsule is absorbed differently by the body than the medication in the tablet, so one product cannot be substituted for the other. Each time you have your prescription filled, look at the tablets or capsules in the bottle and make sure that you have received the right product. If you think you received the wrong medication, talk to your doctor or pharmacist right away. Your doctor will probably start you on a low dose of tizanidine and gradually increase your dose, depending on your response to this medication.  Do not stop taking tizanidine without talking to your doctor. If you suddenly stop taking tizanidine, your heart may beat faster and you may have increased blood pressure or tightness in your muscles. Your doctor will probably decrease your dose gradually.
More Posts
Share by: